Recursion
Salt Lake City, Utah, United States
Recursion is a drug discovery company that utilizes automation and machine learning.
How We Help
Problem Statement
The company aims to industrialize drug discovery and decode biology, thereby improving the cost, timeline, and probability of success in developing new drugs for diseases with high unmet medical need, potentially reducing drug discovery time by a factor of 10.
Core Technology
"Recursion Operating System (OS)," an end-to-end AI-driven drug discovery and development platform combining automation, high-throughput wet labs, robotics, computer vision, and advanced AI/machine learning models. It leverages over 50 petabytes of proprietary biological and chemical data and utilizes the BioHive-2 supercomputer (built with NVIDIA).
Key Differentiators
Integrated TechBio approach with a robust pipeline of AI-enabled assets; one of the world's largest proprietary multimodal biological and chemical datasets (over 50 petabytes); BioHive-2 supercomputer with NVIDIA; aims to improve cost, timeline, and probability of success in drug development by automating workflows and leveraging computational models, potentially reducing drug discovery time by a factor of 10.
Clinical Focus
Indications with high unmet medical need, particularly in oncology (cancer) and rare diseases.
Target Customers
Pharmaceutical companies (partners) and ultimately patients with diseases of high unmet medical need.
Product Stage
R&D
Company Info
- Business Model
- B2B (partnerships with pharmaceutical companies for drug development, licensing, royalties, milestone payments), B2C (future drug sales from internal development)
- Founded
- 2013
- Total Funding
- 1,000,000,000
- Website
- recursion.com
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
Identified as a clinical-stage biotechnology company with a pipeline that includes programs for familial adenomatous polyposis (FAP), hypophosphatasia, advanced solid tumors, biomarker-enriched solid tumors and lymphoma, B-cell malignancies, and HR+ breast cancer.
MedStartr Index Score
?What do you think of Recursion?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.